首页 > 《中国药学：英文版》 > 2018年2期 > FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing

FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing

打印

在线阅读下载PDF 导出详情

摘要未填写

DOI pj0kl6304y/1830851

作者

机构地区不详

出处《中国药学：英文版》 2018年2期

关键词管理局癌症房间药品食物风险

分类 [医药卫生][药学]

出版日期 2018年02月12日（中国Betway体育网页登陆平台首次上网日期，不代表论文的发表时间）

相关文献

1Zhou Fei,Zhou Cai-Cun.Immunotherapy in non-small cell lung cancer: advancements and challenges.医药卫生,2021-05.
2Li Chu-Ling,Song Yong.Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges.医药卫生,2021-09.
3Yu-Sook Jeong;Hye-Suk Han;Sung-Nam Lim;Mi-Jin Kim;Joung-Ho Han;Min-Ho Kang;Dong-Hee Ryu;Ok-Jun Lee;Ki-Hyeong Lee;Seung-Taik Kim.Gallbladder Metastasis of Non-small Cell Lung Cancer Presenting as Acute Cholecystitis.肿瘤,2012-03.
4Siyuan Ren,Mengyao Ma,Chuan He,Yuhui Deng,Xiaoyun Chen,Yonglin Liu,Yangyang Jin,Yansong Liu,Lei Cai,Lin He.Placebo effect in the treatment of non-small cell lung cancer: a meta-analysis.医药卫生,2022-12.
5徐光川;戎铁华;林鹏.ADJUVANT CHEMOTHERAPY FOLLOWING RADICAL SURGERYFOR NON-SMALL CELL LUNG CANCER:A RANDOMIZED STUDY.肿瘤,1999-01.
6林东;王恩华;张志坤;徐洪涛;李庆昌;邱雪杉.EXPRESSION OF PHOSPHO-b-CATENIN AND ITS SIGNIFICANCE IN NON-SMALL CELL LUNG CANCER.肿瘤,2003-01.
7Lin Jiang,Jingbo Zhang,Yan Xu,Heng Xu,Mengzhao Wang.Treating non-small cell lung cancer by targeting the PI3K signaling pathway.医药卫生,2022-12.
8ZONG Min-ru;ZHAO Ying-hao;ZHANG Kun;YANG Long-fei;ZHENG Yong-chen;HE Cheng-yan.Inhibitory Effects of Natural Compound Alantolactone on Human Non-small Cell Lung Cancer A549 Cells.化学,2011-02.
9Gui-Long Li;Yong Zhu;Wei Zheng;Chao-Hui Guo;Chun Chen.Analysis of factors influencing skip lymphatic metastasis in pN2 non-small cell lung cancer.肿瘤,2012-04.
10Xie Yi;Zhang Hong.3-59 Mechanism on X-ray Irradiation Suppressing Radioresistance in Non-small Cell Lung Cancer.物理,2015-01.

来源期刊

中国药学：英文版

相关推荐

同分类资源更多

相关关键词

管理局癌症房间药品食物风险

返回顶部